Bristol-Myers Squibb (NYSE:BMY) Position Boosted by Twin Capital Management Inc.

Twin Capital Management Inc. raised its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 13.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,162 shares of the biopharmaceutical company’s stock after acquiring an additional 9,831 shares during the quarter. Twin Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $4,267,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Herold Advisors Inc. grew its stake in shares of Bristol-Myers Squibb by 3.2% in the 3rd quarter. Herold Advisors Inc. now owns 33,668 shares of the biopharmaceutical company’s stock valued at $1,954,000 after buying an additional 1,051 shares in the last quarter. Kestra Private Wealth Services LLC lifted its holdings in shares of Bristol-Myers Squibb by 9.5% during the third quarter. Kestra Private Wealth Services LLC now owns 139,811 shares of the biopharmaceutical company’s stock worth $8,115,000 after buying an additional 12,121 shares during the last quarter. Metis Global Partners LLC lifted its holdings in shares of Bristol-Myers Squibb by 14.8% during the third quarter. Metis Global Partners LLC now owns 101,772 shares of the biopharmaceutical company’s stock worth $5,907,000 after buying an additional 13,122 shares during the last quarter. Jmac Enterprises LLC lifted its holdings in shares of Bristol-Myers Squibb by 11.4% during the third quarter. Jmac Enterprises LLC now owns 12,171 shares of the biopharmaceutical company’s stock worth $706,000 after buying an additional 1,245 shares during the last quarter. Finally, Signaturefd LLC lifted its holdings in shares of Bristol-Myers Squibb by 0.5% during the third quarter. Signaturefd LLC now owns 105,986 shares of the biopharmaceutical company’s stock worth $6,151,000 after buying an additional 564 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Up 0.1 %

Bristol-Myers Squibb stock traded up $0.05 during mid-day trading on Thursday, hitting $47.89. The stock had a trading volume of 4,518,421 shares, compared to its average volume of 15,692,369. The stock has a 50-day simple moving average of $51.26 and a two-hundred day simple moving average of $51.59. The stock has a market capitalization of $97.06 billion, a PE ratio of 12.46, a P/E/G ratio of 1.49 and a beta of 0.39. Bristol-Myers Squibb has a 12 month low of $47.58 and a 12 month high of $70.93. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.55 by $0.15. The business had revenue of $11.48 billion for the quarter, compared to analysts’ expectations of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The firm’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter last year, the business earned $1.82 earnings per share. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 6.47 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 5.01%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is 62.18%.

Analysts Set New Price Targets

A number of research analysts have recently commented on BMY shares. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Wells Fargo & Company upped their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Finally, Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.